|
Title
|
|
|
|
Clinical achievements of the EORTC Lymphoma Group and aspects of future group strategy
|
|
|
Author
|
|
|
|
|
|
|
Institution/Organisation
|
|
|
|
EORTC Lymphoma Grp
|
|
|
Abstract
|
|
|
|
| Since1964, the EORTC Lymphoma Group has conducted nine consecutive randomized phase III trials on early-stage Hodgkin lymphoma aimed at increasing efficacy while decreasing short- and long-term toxicities. Event-free and overall survival significantly improved from about 50% and 70%, respectively, in the early years to over 80% and 90%, respectively, more recently. Identification of prognostic subgroups appeared to be a successful method to tailor treatment strategies. Radiotherapy fields have become more restricted whereas chemotherapy has become standard. Early PET-CT has been introduced to investigate the possibility of treatment adaptation. Longitudinal quality-of-life assessment has become an integral part of our studies. An ongoing study focuses on the rehabilitation and quality of long-term survival in all 6658 Hodgkin lymphoma patients treated in EORTC trials since the earliest beginning. In advanced stages overall outcome has improved as well with 10-year survival rates of over 75%. (C) 2012 European Organisation for Research and Treatment of Cancer. All rights reserved. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
European journal of cancer : supplements. - Amsterdam, 1990, currens
|
|
|
Publication
|
|
|
|
Amsterdam
:
2012
|
|
|
ISSN
|
|
|
|
1359-6349
[print]
1878-1217
[online]
|
|
|
DOI
|
|
|
|
10.1016/S1359-6349(12)70019-8
|
|
|
Volume/pages
|
|
|
|
10
:1
(2012)
, p. 105-111
|
|
|
ISI
|
|
|
|
000302130800017
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|